ProCE Banner Activity

Tumor-Agnostic Biomarkers and Targeted Treatment of Advanced Colorectal Cancer

Slideset Download
Download this slideset for expert perspectives on best practices in testing for tumor-agnostic and CRC-specific biomarkers—including MSI/MMR, TMB, NTRK fusions, BRAF/RAS mutations, and HER2 amplifications—and use of related targeted therapeutics.

Released: June 03, 2022

Expiration: June 02, 2023

No longer available for credit.

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Seagen Inc.

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC